Results 91 to 100 of about 20,710 (242)
Neprilysin inhibitors with expanded indications
, 2020 Neprilysin is a neutral endopeptidase with broad substrate specificity. Among others, it cleaves natriuretic peptides which have a significant role in the pathomechanism of heart failure.
Szudrawski, Jakub
core
Neprilysin inhibirors in pharmacotherapy of various diseases [PDF]
, 2021 Current research illustrates the role of neprilysin as a possible point of application in the treatment of a number of diseases, including heart failure, diabetes mellitus and Alzheimer's disease.
Derkach, A. Y. +9 more
core
ESC Heart Failure, Volume 12, Issue 2, Page 1119-1131, April 2025.Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi +6 more
wiley +1 more source
Angiotensin Receptor–Neprilysin Inhibition
, 2016 The novel combination sacubitril/valsartan represents a new therapeutic approach in the management of heart failure. With the simultaneous blockage of the enzyme neprilysin (by sacubitril) and angiotensin II receptors (by valsartan), this combination ...
Uri Elkayam, Ofer Havakuk
core +1 more source
Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats
ESC Heart Failure, Volume 12, Issue 2, Page 1304-1315, April 2025.Parts of the figure were drawn by using pictures from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/). Abstract Aims Sacubitril/valsartan (Sac/Val) is used for treatment of heart failure. The effect of Sac/Val on regional dysfunction
Einar Sjaastad Nordén +16 more
wiley +1 more source
Neprilysin Deficiency-Dependent Impairment of Cognitive Functions in a Mouse Model of Amyloidosis [PDF]
, 2018 Alzheimer's disease, responsible for the vast majority of dementia cases in the elderly population, is caused by accumulation of toxic levels of amyloid β peptide (Aβ) in the brain.
Mohajeri, M., Wolfer, David
core
FDG PET/CT imaging and circulating biomarkers of inflammation in desmoplakin cardiomyopathy
ESC Heart Failure, Volume 12, Issue 2, Page 1485-1489, April 2025.Abstract Aims Inflammation has been implicated in the pathogenesis of desmoplakin (DSP) cardiomyopathy, and retrospective studies have described abnormal myocardial fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings in symptomatic patients eventually diagnosed with DSP cardiomyopathy.
Sanjay Divakaran +10 more
wiley +1 more source
, 2006 Accumulation of the beta-amyloid peptide (Abeta) in the brain is a major pathological hallmark of Alzheimer's disease (AD), leading to synaptic dysfunction, neuronal death, and memory impairment.
Mercken, M +21 more
core +1 more source
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad +9 more
wiley +1 more source
The Role of Neprilysin Inhibitors in the Treatment of CV Diseases
, 2020 • Neprilysin has an important role in the etiology of some diseases such as cardiovascular diseases. • Neprilysin inhibitors can improve the prognosis of some cardiovascular diseases.
Margalit, Nizan
core